Theriva Biologics picked as finalist in competition for Merck KGaA’s EMEA  grant
PremiumThe FlyTheriva Biologics picked as finalist in competition for Merck KGaA’s EMEA grant
20d ago
Theriva Biologics Gains Orphan Drug Status for VCN-01
Premium
Company Announcements
Theriva Biologics Gains Orphan Drug Status for VCN-01
1M ago
Theriva announces orphan medicinal product designation by EMA to VCN-01
Premium
The Fly
Theriva announces orphan medicinal product designation by EMA to VCN-01
1M ago
Correct: Theriva Biologics prices $2.5M public offering at $1.75 per share
PremiumThe FlyCorrect: Theriva Biologics prices $2.5M public offering at $1.75 per share
2M ago
Theriva Biologics Advances VCN-01 in VIRAGE Phase 2b Trial
Premium
Company Announcements
Theriva Biologics Advances VCN-01 in VIRAGE Phase 2b Trial
2M ago
Theriva Biologics achieves target patient enrollment in VIRAGE Phase 2b trial
Premium
The Fly
Theriva Biologics achieves target patient enrollment in VIRAGE Phase 2b trial
2M ago
Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested
PremiumMarket NewsUpcoming Stock Splits This Week (August 26 to August 30) – Stay Invested
3M ago
Theriva Biologics announces 1-for-25 reverse stock split
Premium
The Fly
Theriva Biologics announces 1-for-25 reverse stock split
3M ago
Theriva Biologics reports Q2 EPS (43c), consensus (70c)
Premium
The Fly
Theriva Biologics reports Q2 EPS (43c), consensus (70c)
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100